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Objective: To test whether the interleukin-4 (IL-4) gene polymorphisms could be used as markers of
susceptibility for preeclampsia in Taiwan.
Materials and methods: This study included 78 women with preeclampsia and 125 normal controls. A
polymerase chain reactionwas used to analyze the variable number of tandem repeats polymorphism for
the IL-4 gene intron 3. Restriction fragment length polymorphism analysis using endonuclease BsmFI was
performed for the IL-4 gene at the promoter 590 position. The association between the genotype and
disease was examined using Chi-square tests.
Results: We found no signiﬁcant differences in the genotype distributions and allele frequencies for the
IL-4 gene at both promoter and intron 3 regions between the preeclampsia and control groups.
Conclusion: Even though this is the ﬁrst study investigating the association between the promoter region
and intron 3 polymorphisms of IL-4 and preeclampsia worldwide, our data do not support a role of the
IL-4 gene in the pathogenesis of preeclampsia in Taiwanese women.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Preeclampsia is one of the major issues in maternalefetal
medicine [1]. Preeclampsia is characterized by the new onset of
hypertension and proteinuria after the 20th week of gestation. It
occurs in about 6e10% of all pregnancies and results in substantial
maternal and fetal morbidity and mortality [1]. The underlying
etiology of preeclampsia remains unknown even in the 21st
century, despite extensive researches about the pathogenesis of
preeclampsia. Several pathophysiologic abnormalities, such as
abnormal trophoblast differentiation and invasion, placental and
endothelial dysfunction, immune maladaptation, and exaggerateds and Gynecology, National
, National Cheng Kung Uni-
ng), fchang@mail.ncku.edu.tw
bstetrics & Gynecology. Publishedsystemic inﬂammatory response, have been proposed to explain
the development of preeclampsia [2,3]. Among them, the genetic
component in preeclampsia cannot be neglected. Ever since 1968,
preeclampsia has been proposed to be a genetic disease [4e8].
Chesley and Cooper [6] claimed that a possible single gene may be
responsible for preeclampsia. To date, a variety of genes have been
tested for the disease-gene association in preeclampsia. However,
the results remained controversial [5e8]. In 1999, Dr Broughton
Pipkin has pointed out that a cluster of genes, instead of a single
gene, possibly in conjunction with environmental factors, predis-
pose to the development of preeclampsia [9]. Therefore, several
candidate genes must be investigated to identify the diseaseegene
association in preeclampsia [10].
Although the cause of preeclampsia is not understood
completely, the immune system has been implicated in the path-
ophysiology of preeclampsia. With modiﬁcations in the cellular
immunity and increase in activated T cells and cytokines produc-
tion, preeclampsia might be activated [11e14]. In normal preg-
nancy, the trophoblasts encounter decidual uterine natural killerby Elsevier Taiwan LLC. All rights reserved.
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maternal endometrium and reforming the placental spiral arteries
[15]. Placental implantation and development depends largely on a
balance between immune active and suppressive interactions, and
this balance is mainly controlled by cytokines at the maternalefetal
interface [16]. Cytokines produced by T-helper 1 cells, such as tu-
mor necrosis factor-a, interferon-g, and interleukin (IL)-2, may
cause adverse effects on trophoblast growth and development. By
contrast, inﬂammatory cytokines produced by T-helper 2 cells, such
as IL-4, IL-5, IL-6, and IL-10, may downregulate cellular immunity
and induce a placental growth-enhancing effect [16,17].
Although T-helper 2 cytokines may process protective effects for
normal pregnancy, it is of interest that the role of IL-4 is still
controversial in pregnancy. Omu et al [14] demonstrated a
dichotomous role of IL-4 in pregnancy. In their IL-4 study, normal
pregnancy was associated with remarkable increase of IL-4 in the
ﬁrst half of the pregnancy, since IL-4 inhibited the production and
counteracted the effect of tumor necrosis factor-a, and thus pro-
tecting the pregnancy [14]. However, high levels of IL-4 are asso-
ciated with preeclampsia during the second half of pregnancy and
in the puerperium, probably through reducing nitric oxide secre-
tion, and enhancing human leukocyte antigen expression [14].
Although some studies have reported higher levels of IL-4 in
maternal serum were associated with preeclampsia [14,18,19],
others did not observe any differences in the serum levels of IL-4
between preeclampsia and controls [18].
An exaggerated inﬂammatory response to pregnancy may occur
in genetically susceptible women, who carry cytokine gene poly-
morphisms that are prone to upregulate cytokine production [10].
To the best of our knowledge, the studies for the association of IL-4
gene polymorphisms with preeclampsia are still preliminary. In the
study of Fraser et al, only one polymorphism,590 (C > T), in the IL-
4 gene was tested in preeclampsia patients [20]. Recently, Rajaku-
mar et al used Agilent oligonucleotide microarrays for the gene
expression of IL-4, but only 20 cases were included in both pre-
eclampsia and control groups [21]. In Taiwan, the relationships
between polymorphisms of IL-4 gene and autoimmune diseases
[22e25], type 2 diabetes mellitus [26], bronchopulmonary
dysplasia in preterm infants [27], or biliary atresia and asthma in
children [28,29] had been investigated. Nevertheless, no study has
been undertaken of the association between the IL-4 gene and
preeclampsia. Because the prevalences of polymorphisms vary in
different ethnic populations, in this series we tested the hypothesis
whether the polymorphisms within the IL-4 gene are important
risk factors for preeclampsia in Taiwanese women.
Materials and methods
Participants
This study was approved by the National Cheng Kung University
Hospital (NCKUH) Institutional Review Board (IRB No: HR-95-43
and HR-100-066), and all participants gave written informed
consent.
The criteria by which we recruited the participants in this study
were as previously described [30]. From August 1, 2006 to July 31,
2011 at the Department of Obstetrics and Gynecology of NCKUH,
we retrospectively collected 78 cases of severe preeclampsia, HELLP
syndrome (hemolysis, elevated liver enzymes, and low platelet
count), or eclampsia meeting the criteria of the American College of
Obstetricians and Gynecologists [31,32], and another 125 normal
controls. They all delivered at the Department of Obstetrics and
Gynecology of NCKUH, between January 2006 and December 2010.
Patients with severe preeclampsia, HELLP syndrome, or eclampsia
were collected from the medical records of NCKUH. They werecalled back and asked to sign an informed consent after consulta-
tion. During the same time, blood samples were collected from the
normal controls who had given birth in NCKUH after uncompli-
cated pregnancies and who had at least two normal pregnancies,
including the current one. All study participants were matched for
maternal age within 5 years, gestational age, parity, and fetal sex.
None of the normal controls had clinical signs of preeclampsia or
other medical or pregnancy complications. None of the study par-
ticipants were in labor at the time of blood sampling. Both groups
were ethnically Taiwanese population and were enrolled by
random selection in this study.
Preeclampsia was deﬁned as the development of hypertension
that occurred in a pregnant woman known to be normotensive pre-
viously after 20 weeks of gestation, accompanied by new-onset
proteinuria [3,30e32]. Hypertension was deﬁned as systolic blood
pressure 140 mmHg or diastolic blood pressure 90 mmHg on at
least two occasions and 4e6 hours apart after the 20th week of
gestation in women known to be normotensive previously [30e32].
Proteinuria was deﬁned as 300 mg or more protein excretion in
24-hour urine collection, or protein concentration of 300 mg/L or
higher inurine (1þondipstick) [3,30e32]. Severepreeclampsiawas
diagnosed if one or more of the following were present: blood pres-
sure of 160/110mmHgor higher, excretion of 5 g ormore of protein in
a24-hoururine sample, thepresenceofmultiorgan involvement such
asoliguria, pulmonaryedema, visual or cerebral disturbance andpain
in the epigastric area or right upper quadrant, abnormal liver
enzymes and thrombocytopenia (platelet count < 100  109/L)
[3,30e32]. To diagnoseHELLP syndrome, the following criteria had to
be met: hemolysis, deﬁned by increased lactic dehydrogenase
(600 IU/L); elevated liver enzyme levels (aspartate aminotrans-
ferase and alanine aminotransferase  70 IU/L); and thrombocyto-
penia [3,30e32]. Eclampsiawas deﬁned as the onset of convulsion in
awomanwith preeclampsia [3,30e32]. Gestational agewas based on
the precise date of the last menstrual period or/and ultrasound
measurement of the crownerump length in the ﬁrst trimester.
Womenwho met preeclampsia criteria but not severe preeclampsia
were excluded from the study [30]. Other exclusion criteria were as
follows: multiple pregnancies, premature rupture of membranes,
chorioamnionitis, chronic hypertension, diabetes mellitus, autoim-
mune disorders or fetal abnormalities [30].
Genetic studies
We modiﬁed the methods described previously [22e29,33e36]
to examine the polymorphisms of IL-4 gene (promoter region and
intron 3) in preeclampsia and control groups. The gene for IL-4 has
been mapped to the q arm (q23-31) of chromosome 5 [34]. We
checked two polymorphisms located in the IL-4 gene: a functional
polymorphism, repeating a C-to-T substitution at position 590, in
the promoter region of IL-4 [35] and another polymorphism in the
third intron, composed of a variable number of tandem repeats
(VNTR) of a 70-base pair (bp) sequence [36].
Blood samples were obtained from a peripheral vein and then
DNA was extracted from blood using the Puregene System (Gentra
Systems, Inc.Minneapolis,MN, USA) and stored at 4C until analyzed
[30]. About 50 ng of genomic DNAwas mixed with 20 pmol of each
polymerase chain reaction (PCR) primer in a total volume of 25 mL
containing 10 mM Tris-HCl, pH ¼ 8.3, 50 mM KCl, 2.0 mM MgCl2,
0.2 mM of each deoxyribonucleotide triphosphate, and 1 unit of
AmpliTaq DNA polymerase (PerkinElmer, Foster City, CA, USA). The
primers for IL-4 gene promoter 590 were sense 50-ACTAGGCCT
CACCTGATACG-30 and antisense 50-GTTGTAATGCAGTCCTCCTG-30,
and PCR cycling conditions were set as follows: 35 cycles at 94C for
30seconds,57C for30seconds, and72C for30seconds.Theprimers
for IL-4 gene intron 3 were sense 50-AGGCTGAAAGGGGGAAAGC-30
Table 2
Genotype distributions of the BsmFI polymorphism at position 590 in the pro-
moter region of IL-4 gene among women with severe preeclampsia and normal
controls.
Number
of cases
Genotype distributions c2 p
N TT TC CC
Women with severe
preeclampsiaa
78 54 (69.2%) 22 (28.2%) 2 (2.6%) 3.35 0.187
Normal controls 125 86 (68.8%) 39 (31.2%) 0 (0.0%)
a Women with HELLP syndrome or eclampsia were also included.
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conditionswere set as follows: 35 cycles at 94C for 30 seconds, 60C
for 30 seconds, and 72C for 30 seconds [22e29,35,36].
For examining the polymorphism at IL-4 gene promoter region,
the PCR ampliﬁcation product was analyzed using the restriction
fragment length polymorphism method using BsmFI (New England
Biolabs, Beverly, CA, USA) digestion [22e29,35]. The C allele at
position 590 showed up as 192-bp and 60-bp fragments upon
agarose electrophoresis, whereas the T allele was 252 bp in length,
and was encoded at position 590. Thus, the genotypes at this site
were classiﬁed into excisable allelic homozygote (CC) and non-
excisable allelic homozygote (TT), and heterozygote (CT)
[22e29,35]. For IL-4 gene intron 3, 10 mL of PCR ampliﬁcation
product was directly loaded onto a 3% agarose gel containing
ethidium bromide for electrophoresis, and each allele was recog-
nized according to its size. The 70 bp length of VNTRs of the
polymorphism for IL-4 gene intron 3 were classiﬁed as D allele
(183 bp) and I allele (253 bp) [22e29,36].
To detect a newmutation or variation in the PCR products of IL-4
gene promoter and intron 3, we used single strand conformation
polymorphism and denaturing gradient gel electrophoresis [37].
We also did direct sequencing for the representative samples or
equivocal results detected by single strand conformation poly-
morphism and denaturing gradient gel electrophoresis as described
by Chang and Kidd [38].
Statistical analysis
Data of clinical characteristics and pregnancy outcomes are
expressed as mean ± standard error of mean. Genotype and allele
frequencies were compared by c2 testing, using the statistical
package SPSS (SPSS Inc, Chicago, IL, USA). Yates' correction of con-
tinuity was used when an observed number was 5. A p value
<0.05 was considered statistically signiﬁcant.
Results
Clinical characteristics and pregnancy outcomes of 78 cases of
severe preeclampsia and 125 normal controls are shown in Table 1.
The normal controls and women with severe preeclampsia did not
differ in their age, parity, or the sex of newborn babies. In the
pregnancy outcomes of women with severe preeclampsia, earlier
gestational age, less birth weight, and lower Apgar score of their
newborns were found. This implies that preeclampsia is an
important cause of perinatal morbidity and mortality [1e3].
Genotype distributions and allele frequencies of the BsmFI
polymorphism at the position 590 in the promoter region of the
IL-4 gene among women with severe preeclampsia and normal
controls are given in Tables 2 and 3. Genotype was determined inTable 1
Clinical characteristics and pregnancy outcomes of women with severe pre-
eclampsia and normal controls.
Severe preeclampsiaa Normal controls
Number of cases 78 125
Maternal age, y 31.2 ± 5.2 29.9 ± 4.5
Primiparous, % 60.3 51.2
Multiparous, % 39.7 48.8
Gestational age, wk 34.9 ± 3.7** 38.6 ± 1.6**
Birth weight, g 2129 ± 899** 3202 ± 434**
APGAR score at 1 min 6.1 ± 2.4** 8.7 ± 0.8**
APGAR score at 5 min 8.5 ± 1.4** 9.9 ± 0.4**
Sex Female (%) 48.7% 51.2%
Male (%) 51.3% 48.8%
**p < 0.001 vs. normal controls.
a Women with HELLP syndrome or eclampsia were also included.the 78 women with severe preeclampsia (including HELLP syn-
drome and eclampsia) and 125 normal controls. Overall, three
genotypes (T/T, C/T, C/C) and two alleles (T, C) were seen. The
frequency of homozygotes (T/T) was 69.2% (54 of 78 persons) in
women with severe preeclampsia and 68.8% (86 of 125 persons) in
normal controls. The frequency of homozygotes (C/C) was 2.6% (2 of
78 persons) in women with severe preeclampsia but not detected
(0 of 125 persons) in normal controls. The allele frequency of T
alleles was 83.3% (130 of 156 alleles) in women with severe pre-
eclampsia and 84.4% (211 of 250 alleles) in normal controls. The
allele frequency of C alleles was 16.7% (26 of 156 alleles) in women
with severe preeclampsia and 15.6% (39 of 250 alleles) in normal
controls. For the BsmFI polymorphism at the position 590 in the
promoter region of IL-4 gene, neither genotype distributions nor
allele frequencies showed statistically signiﬁcant differences
among the women with severe preeclampsia and normal controls.
Genotype distributions and allele frequencies of the insertion/
deletion (I/D) of the 70 bp VNTR polymorphism within intron 3 of
IL-4 gene among women with severe preeclampsia and normal
controls are given in Tables 4 and 5. Overall, three genotypes (D/D,
D/I, I/I) and two alleles (D, I) were seen. The frequency of homo-
zygotes for the deletion allele (D/D) was 66.7% (52 of 78 persons) in
women with severe preeclampsia and 68.8% (86 of 125 persons) in
normal controls. The frequency of homozygotes for the insertion
allele (I/I) was 1.3% (1 of 78 persons) in women with severe pre-
eclampsia and 0.8% (1 of 125 persons) in normal controls. The allele
frequency of D alleles was 82.7% (129 of 156 alleles) inwomenwith
severe preeclampsia group and 84% (210 of 250 alleles) in normal
controls. The allele frequency of I alleles was 17.3% (27 of 156 al-
leles) inwomenwith severe preeclampsia group and 16% (40 of 250
alleles) in normal controls. No statistically signiﬁcant differences
were observed in genotype distributions and allele frequencies of
the deletion/insertion of the 70 bp VNTR polymorphism within
intron 3 of IL-4 gene among women with severe preeclampsia and
normal controls.
Discussion
Becausepreeclampsia implies a genetic susceptibility [4e9], it isof
interest to investigate which speciﬁc genetic loci are involved.
Determination of such genetic factors would assist in identifyingTable 3
Allele frequencies of the BsmFI polymorphism at position 590 in the promoter
region of IL-4 gene among women with severe preeclampsia and normal controls.
Numbers of
alleles (2N)
Allele frequencies c2 p
2N T C
Women with severe
preeclampsiaa
156 152 (51.4%) 144 (48.6%) 2.53 0.11
Normal controls 250 90 (44.1%) 114 (55.9%)
a Women with HELLP syndrome or eclampsia were also included.
Table 4
Genotype distributions of the insertion/deletion (I/D) of the 70 base pair variable
number of tandem repeat polymorphismwithin intron 3 of IL-4 gene amongwomen
with severe preeclampsia and normal controls.
Number
of cases
Genotype distributions c2 p
N DD D I I I
Women with severe
preeclampsiaa
78 52 (66.7%) 25 (32.0%) 1 (1.3%) 0.188 0.91
Normal controls 125 86 (68.8%) 38 (30.4%) 1 (0.8%)
a Women with HELLP syndrome or eclampsia were also included.
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promoter and intron 3 polymorphisms at the IL-4 gene in pre-
eclampsia.However,wedidnotﬁndanassociationbetween IL-4gene
polymorphisms and preeclampsia, especially severe preeclampsia.
Our study is also the ﬁrst to investigate the association between IL-4
gene polymorphisms and preeclampsia in Taiwanese women.
Because the ethnic difference might play an important role in dis-
easeegene association studies [39], we cannot adopt the conclusion
from other countries without doing our own studies in Taiwanese
population. The ﬁndings in this study are of great help for under-
standing the pathogenesis of preeclampsia in Taiwanese women.
From our results, we can rule out the role of IL-4 gene poly-
morphisms in the pathogenesis of preeclampsia in Taiwanese
women. Our conclusions were different from previous studies. In
the study of Fraser et al undertaken in the UK, only one
polymorphism, 590 (C/T) polymorphism, at the IL-4 gene was
tested in preeclampsia [20]. They found that there was a marked
trend for an association between IL-4 e590 (C/T) single nucleo-
tide polymorphisms and preeclampsia with a prevalence of TT
homozygous women in this group [20]. Besides, Rajakumar et al
[21] used microarray analysis for the gene expression of IL-4 in
women with preeclampsia in the USA. The maternal race was
mainly Caucasian [21], and they observed that the gene expression
of IL-4 was reduced in severe preeclampsia [21].
There are some possible hypotheses that could explain our re-
sults. One explanation is the deﬁnition of inclusion and exclusion
criteria for study participants. For example, the severity of pre-
eclampsia might affect the results [40]. The diagnostic criteria for
preeclampsia used in our study were the same as previous studies
investigating for the role of IL-4 gene polymorphisms in the path-
ogenesis of preeclampsia [20,21]. In our present study, womenwho
met preeclampsia criteria but not severe preeclampsia were
excluded from the study, whereas women with mild preeclampsia
were included in previous studies [20,21].
Other reasons for our negative results might be contributed to
the complex interactions between genetics and environment [41].
Although preeclampsia is generally considered to be a multifacto-
rial disease, environmental factors for preeclampsia, such as diet,
obesity, stress, smoking, and other social elements during preg-
nancy, may impact in the development of preeclampsia. Moreover,Table 5
Allele frequencies of the insertion/deletion of the 70 base pair variable number of
tandem repeats polymorphism within intron 3 of IL-4 gene among women with
severe preeclampsia and normal controls.
Number of
alleles (2N)
Allele number
(frequency)
c2 p
2N D I
Women with severe
preeclampsiaa
156 129 (82.7%) 27 (17.3%) 0.119 0.73
Normal controls 250 210 (84.0%) 40 (16.0%)
a Women with HELLP syndrome or eclampsia were also included.these environmental factors may be very different among races
[30,41]. The limitation of our study is that we did not analyze the
interaction and comorbidity among environmental risk factors,
polymorphisms of IL-4 gene and preeclampsia.
In conclusion, preeclampsia might involve a battery of different
genes [41]. In this series, we observed that polymorphisms of IL-4
gene do not play a major role in the development of preeclamp-
sia in the Taiwanese women. Multilocus or haplotype analysis,
rather than a single locus study, might be a preferable strategy in
the future in order to obtain more accurate results between genetic
susceptibility and preeclampsia.
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